INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2001

Glucosamine sulphate prevented progressive joint-space narrowing and improved symptoms over 3 years in knee osteoarthritis patients.

In a 3-year randomized trial, 212 patients with knee osteoarthritis received either 1500 mg oral glucosamine sulphate or placebo once daily. Patients on placebo experienced progressive joint-space narrowing with a mean joint-space loss of -0.31 mm (95% CI -0.48 to -0.13), whereas patients taking glucosamine sulphate had no significant loss (-0.06 mm, 95% CI -0.22 to 0.09). WOMAC scores showed symptoms worsened slightly on placebo but improved with glucosamine sulphate, with no differences in safety or reasons for early withdrawal between groups.

Study type
Randomised, double-blind, placebo-controlled trial
Who was studied
212 patients with knee osteoarthritis
What was measured
Mean and minimum joint-space width, WOMAC osteoarthritis index scores, safety

THE PAPER

Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial.

Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, Giacovelli G, Henrotin Y, Dacre JE, Gossett C. Lancet, 2001.

PubMed 11214126 ↗DOI 10.1016/s0140-6736(00)03610-2 ↗

Bones & muscles

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.